Table 3.
AEs, Patient Adherence, and Drug Costs in Each Group
| BCQ Group | VA14 Group | VAC Group | p values | |||
|---|---|---|---|---|---|---|
| BCQ vs VA14 | BCQ vs VAC | VA14 vs VAC | ||||
| Adverse events | 22.95% (14/61) | 9.38% (6/64) | 1.45% (1/69) | 0.038 | 0.002 | 0.041 |
| Nausea | 8.20% (4/61) | 6.25% (4/64) | 1.45% (1/69) | 0.944 | 0.131 | 0.146 |
| Diarrhea | 3.28% (2/61) | 0 | 0 | 0.144 | 0.488 | N.A. |
| Dizziness | 1.64% (1/61) | 1.56% (1/64) | 0 | 0.973 | 0.469 | 0.957 |
| Taste distortion | 1.64% (1/61) | 0 | 0 | 0.304 | 0.286 | N.A. |
| Skin rash | 1.64% (1/61) | 0 | 0 | 0.304 | 0.286 | N.A. |
| Tongue discolouration | 1.64% (1/61) | 0 | 0 | 0.304 | 0.286 | N.A. |
| Darkened stool | 4.92% (3/61) | 0 | 0 | 0.073 | 0.101 | N.A. |
| Others | 1.64% (1/61) | 1.56% (1/64) | 0 | 0.973 | 0.286 | 0.481 |
| Adverse events caused drop-out | 0 | 0 | 0 | N.A. | N.A. | N.A. |
| Compliance | 81.33% (61/75) | 85.33% (64/75) | 93.24% (69/74) | 0.585 | 0.029 | 0.119 |
| Drug cost (RMB) | 317.19 | 285.06 | 414.33 | |||
Notes: The bold values indicated p values <0.05. VA14, vonoprazan 20 mg b.i.d. + amoxicillin 750 mg t.i.d. for 14 days. VAC, VA14 + Jinghua Weikang Capsule 160 mg t.i.d for 14 days. BCQ, bismuth-containing quadruple therapy, esomeprazole 20 mg b.i.d + AMO 1000 mg b.i.d + furazolidone 100 mg b.i.d + 0.6 g bismuth potassium citrate b.i.d for 14 days.